CXCR4 Expression in Prostate Cancer Progenitor Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Feb 24

PMID 22359577

Citations 79

Authors

Anna Dubrovska

Jimmy Elliott

Richard J Salamone

Gennady D Telegeev

Alexander E Stakhovsky

Ihor B Schepotin

Feng Yan

Yan Wang

Laure C Bouchez

Sumith A Kularatne

James Watson

Christopher Trussell

Venkateshwar A Reddy

Charles Y Cho

Peter G Schultz

Affiliations

Soon will be listed here.

Abstract

Tumor progenitor cells represent a population of drug-resistant cells that can survive conventional chemotherapy and lead to tumor relapse. However, little is known of the role of tumor progenitors in prostate cancer metastasis. The studies reported herein show that the CXCR4/CXCL12 axis, a key regulator of tumor dissemination, plays a role in the maintenance of prostate cancer stem-like cells. The CXCL4/CXCR12 pathway is activated in the CD44(+)/CD133(+) prostate progenitor population and affects differentiation potential, cell adhesion, clonal growth and tumorigenicity. Furthermore, prostate tumor xenograft studies in mice showed that a combination of the CXCR4 receptor antagonist AMD3100, which targets prostate cancer stem-like cells, and the conventional chemotherapeutic drug Taxotere, which targets the bulk tumor, is significantly more effective in eradicating tumors as compared to monotherapy.

Citing Articles

Cancer-associated fibroblasts and prostate cancer stem cells: crosstalk mechanisms and implications for disease progression.

Chen H, Fang S, Zhu X, Liu H Front Cell Dev Biol. 2024; 12:1412337.

PMID: 39092186 PMC: 11291335. DOI: 10.3389/fcell.2024.1412337.

CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas.

Virgili A, Salazar J, Gallardo A, Lopez-Pousa A, Teres R, Bague S Diagnostics (Basel). 2024; 14(11).

PMID: 38893721 PMC: 11172351. DOI: 10.3390/diagnostics14111195.

Genome-wide CRISPR/Cas9 screen reveals JunB downmodulation of HIV co-receptor CXCR4.

Schulze W, Gregory D, Johnson M, Lange M Front Microbiol. 2024; 15:1342444.

PMID: 38835488 PMC: 11149427. DOI: 10.3389/fmicb.2024.1342444.

The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.

Ullah A, Jiao W, Shen B Cell Mol Biol Lett. 2024; 29(1):73.

PMID: 38745115 PMC: 11094955. DOI: 10.1186/s11658-024-00591-9.

Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways.

MacLean M, Walker O, Arun R, Fernando W, Marcato P Int J Mol Sci. 2024; 25(7).

PMID: 38612911 PMC: 11012648. DOI: 10.3390/ijms25074102.

References

Arnold J, Isaacs J . Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer. 2002; 9(1):61-73. PMC: 4124629. DOI: 10.1677/erc.0.0090061. View

Singh S, Singh U, Grizzle W, Lillard Jr J . CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004; 84(12):1666-76. DOI: 10.1038/labinvest.3700181. View

Vishnu P, Tan W . Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther. 2010; 3:39-51. PMC: 2895780. DOI: 10.2147/ott.s5818. View

Cooper C, Chay C, Pienta K . The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia. 2002; 4(3):191-4. PMC: 1531692. DOI: 10.1038/sj.neo.7900224. View

Dalerba P, Cho R, Clarke M . Cancer stem cells: models and concepts. Annu Rev Med. 2006; 58:267-84. DOI: 10.1146/annurev.med.58.062105.204854. View

Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim W, Cao W . Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate. 2009; 69(13):1460-9. DOI: 10.1002/pros.21008. View

Dubrovska A, Kim S, Salamone R, Walker J, Maira S, Garcia-Echeverria C . The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 2009; 106(1):268-73. PMC: 2629188. DOI: 10.1073/pnas.0810956106. View

Vander Griend D, Karthaus W, Dalrymple S, Meeker A, DeMarzo A, Isaacs J . The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008; 68(23):9703-11. PMC: 3072758. DOI: 10.1158/0008-5472.CAN-08-3084. View

Mulholland D, Xin L, Morim A, Lawson D, Witte O, Wu H . Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009; 69(22):8555-62. PMC: 2783355. DOI: 10.1158/0008-5472.CAN-08-4673. View

10.

Huang H, Tindall D . FOXO factors: a matter of life and death. Future Oncol. 2006; 2(1):83-9. DOI: 10.2217/14796694.2.1.83. View

11.

Lawson D, Zong Y, Memarzadeh S, Xin L, Huang J, Witte O . Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010; 107(6):2610-5. PMC: 2823887. DOI: 10.1073/pnas.0913873107. View

12.

Zlotnik A . New insights on the role of CXCR4 in cancer metastasis. J Pathol. 2008; 215(3):211-3. DOI: 10.1002/path.2350. View

13.

Ehtesham M, Mapara K, Stevenson C, Thompson R . CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett. 2008; 274(2):305-12. PMC: 2628453. DOI: 10.1016/j.canlet.2008.09.034. View

14.

Burger J, Burger M, Kipps T . Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999; 94(11):3658-67. View

15.

Passegue E, Wagner E, Weissman I . JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell. 2004; 119(3):431-43. DOI: 10.1016/j.cell.2004.10.010. View

16.

Wu Y, Peng H, Cui M, Whitney N, Huang Y, Zheng J . CXCL12 increases human neural progenitor cell proliferation through Akt-1/FOXO3a signaling pathway. J Neurochem. 2009; 109(4):1157-67. PMC: 2679099. DOI: 10.1111/j.1471-4159.2009.06043.x. View

17.

Goldstein A, Huang J, Guo C, Garraway I, Witte O . Identification of a cell of origin for human prostate cancer. Science. 2010; 329(5991):568-71. PMC: 2917982. DOI: 10.1126/science.1189992. View

18.

Zeng Z, Samudio I, Munsell M, An J, Huang Z, Estey E . Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 2006; 5(12):3113-21. DOI: 10.1158/1535-7163.MCT-06-0228. View

19.

Vandercappellen J, Van Damme J, Struyf S . The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267(2):226-44. DOI: 10.1016/j.canlet.2008.04.050. View

20.

Richardson G, Robson C, Lang S, Neal D, Maitland N, Collins A . CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci. 2004; 117(Pt 16):3539-45. DOI: 10.1242/jcs.01222. View